News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. discusses developing oral crofelemer for pediatric patients with Intestinal Failure (IF) due to MVID, aiming for Breakthrough Therapy Designation. Initial results show reductions in PS needs -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. advances towards full FDA approval of Crofelemer for treating chemotherapy-induced diarrhea in dogs, supported by positive trial results -
